Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

January 1, 2021

Study Completion Date

January 1, 2021

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Anlotinib Plus Icotinib

"Anlotinib:12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib:125 mg/tablet,three times a day,fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."

Trial Locations (5)

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Unknown

Hebei Provincial People's Hospital, Shijiazhuang

Neimenggu Autonomous Region People's Hospital, Hohhot

Neimenggu Medical University Affiliated Hospital, Hohhot

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER